02
eTAO

Treatment Decision Pathways

Three Major Pathways to Choose the Best Treatment

Each pathway targets a distinct mechanism in dry eye disease, enabling clinicians to select the most appropriate therapeutic strategy.

Pathway 1

Increase or Restore Meibomian Gland Secretory Function

Thermotherapies IPL QMR Jett LLLT Orbicular Stimulation
Pathway 2

Increase or Restore Lacrimal Gland Secretory Function

Outflow Modulation
Lacrimal Outflow Modulation Therapies
Plugs Intracanalicular Gels Thermal Occlusion Surgical Occlusion
Gland Stimulation
Krause & Wolfring stimulation by Jett
Secretagogues (Tear Stimulants)
Cholinergic Agonists
Pilocarpine Cevimeline
Nasal Neurostimulation Agents
Varenicline nasal Tyrvaya
Pathway 3

Enhance or Restore Goblet Cell-Mediated Mucin Secretion

Mucin Secretagogues / Goblet Cell Modulators
Diquafosol Rebamipide
Lipid Layer Modulators
Omega-3 Supplements / Lipid Nutraceuticals Lipid-based Artificial Tears
Supplementation
Tear Substitutes (Artificial Tears / Lubricants) Goblet Cell stimulation by Jett
eTAO

eTAO Assistance in Selecting the Best Therapeutic Option

The eTAO scoring system integrates clinical findings across all axes to guide the selection of the most appropriate treatment pathway for each patient profile.

Explore Treatments